WHWK
Whitehawk Therapeutics Inc.

6,387
Mkt Cap
$184.07M
Volume
58,192.00
52W High
$4.48
52W Low
$1.39
PE Ratio
8.22
WHWK Fundamentals
Price
$3.94
Prev Close
$3.90
Open
$3.87
50D MA
$3.03
Beta
1.07
Avg. Volume
118,317.05
EPS (Annual)
-$0.3328
P/B
1.35
Rev/Employee
$310,652.17
$4.07
Loading...
Loading...
News
all
press releases
Ally Bridge Group NY LLC Takes $1.55 Million Position in Whitehawk Therapeutics, Inc. $WHWK
Ally Bridge Group NY LLC acquired a new stake in Whitehawk Therapeutics, Inc. (NASDAQ:WHWK - Free Report) in the 3rd quarter, according to the company in its most recent filing with the Securities...
MarketBeat·2d ago
News Placeholder
More News
News Placeholder
2,849,402 Shares in Whitehawk Therapeutics, Inc. $WHWK Purchased by Avoro Capital Advisors LLC
Avoro Capital Advisors LLC acquired a new position in shares of Whitehawk Therapeutics, Inc. (NASDAQ:WHWK - Free Report) in the 3rd quarter, according to its most recent 13F filing with the...
MarketBeat·3d ago
News Placeholder
Whitehawk Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights
Whitehawk Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights Whitehawk Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent...
PR Newswire·5d ago
News Placeholder
Insider Selling: Whitehawk Therapeutics (NASDAQ:WHWK) CEO Sells 5,100 Shares of Stock
Whitehawk Therapeutics, Inc. (NASDAQ:WHWK - Get Free Report) CEO David James Lennon sold 5,100 shares of the stock in a transaction dated Monday, March 2nd. The shares were sold at an average price...
MarketBeat·6d ago
News Placeholder
David James Lennon Sells 5,100 Shares of Whitehawk Therapeutics (NASDAQ:WHWK) Stock
Whitehawk Therapeutics, Inc. (NASDAQ:WHWK - Get Free Report) CEO David James Lennon sold 5,100 shares of Whitehawk Therapeutics stock in a transaction that occurred on Monday, March 2nd. The shares...
MarketBeat·7d ago
News Placeholder
Aadi Bioscience Conference: Whitehawk Unveils 3-Program ADC Pipeline, Targets First Data in 2027
Whitehawk Therapeutics CEO Dave Lennon outlined the company's strategy and near-term milestones at the Inaugural Life Sciences Conference in Miami, describing a three-program antibody-drug conjugate...
MarketBeat·7d ago
News Placeholder
Aadi Bioscience Conference: Whitehawk CEO Details 3-Program ADC Pipeline, First Data Seen in 2027
Whitehawk Therapeutics CEO Dave Lennon presented at TD Cowen's 46th Annual Healthcare Conference, outlining the company's strategy to develop a portfolio of next-generation antibody-drug conjugates...
MarketBeat·14d ago
News Placeholder
Whitehawk Therapeutics to Participate in Upcoming Investor Conferences
Whitehawk Therapeutics to Participate in Upcoming Investor Conferences Whitehawk Therapeutics to Participate in Upcoming Investor Conferences PR Newswire MORRISTOWN, N.J., Feb. 26, 2026 MORRISTOWN...
PR Newswire·19d ago
News Placeholder
Aadi Bioscience Conference: CEO Spotlights Whitehawk ADC Pipeline, Cash Runway Through 2028
Whitehawk Therapeutics CEO Dave Lennon outlined the company's antibody-drug conjugate (ADC) strategy and pipeline during an Annual Healthcare Conference presentation, highlighting two clinical-stage...
MarketBeat·20d ago
News Placeholder
Tempus AI Stock Before Q4 Earnings Release: To Buy or Not to Buy?
TEM heads into Q4 earnings with expected 82.8% revenue growth, rising oncology momentum and a premium valuation clouding near-term upside.
Zacks·27d ago
<
1
2
...
>

Latest WHWK News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.